John is the Chief Technology Officer of Integral. He has over 39 years of experience in the pharmaceutical industry—29 years at GSK R&D including 11 years on its executive leadership team. John has participated in the research and development of scores of commercial products. John’s most recent roles before Integral were SVP of GSK’s science and technology platforms and SVP of a small in silico drug discovery unit. John is a proponent of seeking, integrating and implementing innovative approaches to drug discovery and development. He led several GSK innovation initiatives through internal teams, technology acquisitions and partnerships. John conceptualized and is currently senior science advisor to the Accelerating Therapeutics for Opportunities in Medicine (ATOM) consortium – an open membership, public/private partnership currently comprised of Pharma, Tech, Lawrence Livermore National Laboratory, Frederick National Laboratory for Cancer Research, and the University of California, San Francisco. John is also Chair of the Executive Committee of the Alliance for Artificial Intelligence in Healthcare, an organization formed to foster improved healthcare by responsible investment, invention and innovation in artificial intelligence. John received his PhD from Penn State University in biological chemistry.
